Ann Liver Transplant.  2023 Nov;3(2):86-93. 10.52604/alt.23.0023.

ADV score is a reliable surrogate biomarker of hepatocellular carcinoma in liver resection and transplantation

• Hwang S
• Jung DH
• Song GW

• KMID: 2560928
• DOI: http://doi.org/10.52604/alt.23.0023

Abstract

A composite score, known as the ADV score, which is calculated by multiplying the levels of α-fetoprotein and des-γ-carboxy prothrombin along with tumor volume, has been demonstrated as an all-encompassing prognostic indicator for hepatocellular carcinoma (HCC) subsequent to hepatic resection and liver transplantation. This ADV score serves as a quantifiable metric that reflects the underlying characteristics of the tumor. This study was designed to validate the prognostic impact of ADV score in patients who underwent hepatic resection or liver transplantation for HCC through a collective review of twelve studies. The role of ADV score in hepatic resection was assessed in eight studies including five single-center studies, two multi-center studies and one international study. The role of ADV score in liver transplantation was assessed in five studies including four single-center studies and one Korea nationwide multi-center study. The culmination of evidence from these twelve investigations affirms the ADV score's role as a comprehensive surrogate biomarker for predicting the prognosis following hepatic resection or liver transplantation in patients diagnosed with HCC. The utilization of the ADV score for prognostic predictions offers a dependable means to inform the management of patients across varying stages of HCC, facilitating the tailoring of individualized postoperative follow-up plans based on the assessed risk of HCC recurrence.

Keyword

Hepatocellular carcinoma; Hepatic resection; Liver transplantation; Prognostic prediction; Microvascular invasion

Reference

1. Hwang S, Lee YJ, Kim KH, Ahn CS, Moon DB, Ha TY, et al. 2015; The impact of tumor size on long-term survival outcomes after resection of solitary hepatocellular carcinoma: single-institution experience with 2558 patients. J Gastrointest Surg. 19:1281–1290. DOI: 10.1007/s11605-015-2849-5. PMID: 25956724.

2. Hwang S, Song GW, Lee YJ, Kim KH, Ahn CS, Moon DB, et al. 2016; Multiplication of tumor volume by two tumor markers is a post-resection prognostic predictor for solitary hepatocellular carcinoma. J Gastrointest Surg. 20:1807–1820. DOI: 10.1007/s11605-016-3187-y. PMID: 27311982.

3. Hwang S, Song GW, Ahn CS, Kim KH, Moon DB, Ha TY, et al. 2021; Quantitative prognostic prediction using ADV score for hepatocellular carcinoma following living donor liver transplantation. J Gastrointest Surg. 25:2503–2515. DOI: 10.1007/s11605-021-04939-w. PMID: 33532981.

4. Hwang S, Song GW, Ahn CS, Kim KH, Moon DB, Ha TY, et al. 2021; Salvage living donor liver transplantation for hepatocellular carcinoma recurrence after hepatectomy: quantitative prediction using ADV score. J Hepatobiliary Pancreat Sci. 28:1000–1013. DOI: 10.1002/jhbp.863. PMID: 33175453.

5. Mazzaferro V, Sposito C, Zhou J, Pinna AD, De Carlis L, Fan J, et al. 2018; Metroticket 2.0 model for analysis of competing risks of death after liver transplantation for hepatocellular carcinoma. Gastroenterology. 154:128–139. DOI: 10.1053/j.gastro.2017.09.025. PMID: 28989060.

6. Jung DH, Hwang S, Lee YJ, Kim KH, Song GW, Ahn CS, et al. 2019; Small hepatocellular carcinoma with low tumor marker expression benefits more from anatomical resection than tumors with aggressive biology. Ann Surg. 269:511–519. DOI: 10.1097/SLA.0000000000002486. PMID: 28837444.

7. Park GC, Hwang S, Park YH, Choi JU. Korean Liver Cancer Study Group. 2020; Validation of prognostic impact of ADV score for resection of hepatocellular carcinoma: analysis using Korea Liver Cancer Registry Database. Ann Surg Treat Res. 98:235–246. DOI: 10.4174/astr.2020.98.5.235. PMID: 32411628. PMCID: PMC7200605.

8. Hwang S, Moon DB, Kim KH, Ahn CS, Song GW, Jung DH, et al. 2021; Prognostic accuracy of the ADV score following resection of hepatocellular carcinoma with portal vein tumor thrombosis. J Gastrointest Surg. 25:1745–1759. DOI: 10.1007/s11605-020-04800-6. PMID: 32948961.

9. Hwang S, Kim KH, Moon DB, Ahn CS, Ha TY, Song GW, et al. 2021; Prediction of post-resection prognosis using the ADV score for huge hepatocellular carcinomas ≥13 cm. J Liver Cancer. 21:45–57. DOI: 10.17998/jlc.21.1.45. PMID: 37384269. PMCID: PMC10035719.

10. Kang WH, Hwang S, Kaibori M, Kim JM, Kim KS, Kobayashi T, et al. 2023; Validation of quantitative prognostic prediction using ADV score for resection of hepatocellular carcinoma: a Korea-Japan collaborative study with 9200 patients. J Hepatobiliary Pancreat Sci. 30:993–1005. DOI: 10.1002/jhbp.1319. PMID: 36808234.

11. Ha SM, Hwang S, Park JY, Lee YJ, Kim KH, Song GW, et al. 2018; Validation of the OncoHepa test, a multigene expression profile test, and the tumor marker-volume score to predict postresection outcome in small solitary hepatocellular carcinomas. Ann Surg Treat Res. 95:303–311. DOI: 10.4174/astr.2018.95.6.303. PMID: 30505821. PMCID: PMC6255750.

12. Hwang S, Joh JW, Wang HJ, Kim DG, Kim KS, Suh KS, et al. 2018; Prognostic prediction models for resection of large hepatocellular carcinoma: a Korean multicenter study. World J Surg. 42:2579–2591. DOI: 10.1007/s00268-018-4468-2. PMID: 29340726.

13. Park GC, Hwang S, You YK, Choi Y, Kim JM, Joo DJ, et al. 2023; Quantitative prediction of posttransplant hepatocellular carcinoma prognosis using ADV score: validation with Korea-nationwide transplantation registry database. J Gastrointest Surg. 27:1353–1366. DOI: 10.1007/s11605-023-05670-4. PMID: 37039979.

14. Hwang S, Lee KJ, Moon DB, Song GW, Jung DH, Kim YK, et al. 2022; Prognostic impact of serum soluble PD-1 and ADV score for living donor liver transplantation in patients with previously untreated hepatocellular carcinoma. Ann Surg Treat Res. 102:46–54. DOI: 10.4174/astr.2022.102.1.46. PMID: 35071119. PMCID: PMC8753378.

15. Lencioni R, Llovet JM. 2010; Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 30:52–60. DOI: 10.1055/s-0030-1247132. PMID: 20175033.

16. Galizia MS, Töre HG, Chalian H, Yaghmai V. 2011; Evaluation of hepatocellular carcinoma size using two-dimensional and volumetric analysis: effect on liver transplantation eligibility. Acad Radiol. 18:1555–1560. DOI: 10.1016/j.acra.2011.08.011. PMID: 21962475.

17. Botea F, Marconi M, Lutman F, Balzarini L, Roncalli M, Montorsi M, et al. 2010; Radiological estimation of size in colorectal liver metastases: is it reliable? Comparison with post-resectional measurements. Updates Surg. 62:21–26. DOI: 10.1007/s13304-010-0004-0. PMID: 20845097.

18. Kim HD, Shim JH, Kim GA, Shin YM, Yu E, Lee SG, et al. 2015; Optimal methods for measuring eligibility for liver transplant in hepatocellular carcinoma patients undergoing transarterial chemoembolization. J Hepatol. 62:1076–1084. DOI: 10.1016/j.jhep.2014.12.013. PMID: 25529626.

19. Kang WH, Hwang S, Song GW, Lee YJ, Kim KH, Ahn CS, et al. 2017; Prognostic effect of transarterial chemoembolization-induced complete pathological response in patients undergoing liver resection and transplantation for hepatocellular carcinoma. Liver Transpl. 23:781–790. DOI: 10.1002/lt.24752. PMID: 28240808.

20. Renzulli M, Brocchi S, Cucchetti A, Mazzotti F, Mosconi C, Sportoletti C, et al. 2016; Can current preoperative imaging be used to detect microvascular invasion of hepatocellular carcinoma? Radiology. 279:432–442. DOI: 10.1148/radiol.2015150998. PMID: 26653683.

21. Min JH, Kim YK, Lim S, Jeong WK, Choi D, Lee WJ. 2015; Prediction of microvascular invasion of hepatocellular carcinomas with gadoxetic acid-enhanced MR imaging: impact of intra-tumoral fat detected on chemical-shift images. Eur J Radiol. 84:1036–1043. DOI: 10.1016/j.ejrad.2015.03.002. PMID: 25818729.

22. Shirabe K, Toshima T, Kimura K, Yamashita Y, Ikeda T, Ikegami T, et al. 2014; New scoring system for prediction of microvascular invasion in patients with hepatocellular carcinoma. Liver Int. 34:937–941. DOI: 10.1111/liv.12459. PMID: 24393295.

23. Poté N, Cauchy F, Albuquerque M, Voitot H, Belghiti J, Castera L, et al. 2015; Performance of PIVKA-II for early hepatocellular carcinoma diagnosis and prediction of microvascular invasion. J Hepatol. 62:848–854. DOI: 10.1016/j.jhep.2014.11.005. PMID: 25450201.